Next Article in Journal / Special Issue
mRNA Vaccines against Flaviviruses
Previous Article in Journal
Construction and Immunogenicity Comparison of Three Virus-Like Particles Carrying Different Combinations of Structural Proteins of Avian Coronavirus Infectious Bronchitis Virus
Previous Article in Special Issue
HIV mRNA Vaccines—Progress and Future Paths
 
 
Review

SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond

Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Steven M. Varga
Vaccines 2021, 9(2), 147; https://doi.org/10.3390/vaccines9020147
Received: 8 January 2021 / Revised: 29 January 2021 / Accepted: 6 February 2021 / Published: 12 February 2021
(This article belongs to the Special Issue The Past, Present, and Future of mRNA Vaccines)
To successfully protect against pathogen infection, a vaccine must elicit efficient adaptive immunity, including B and T cell responses. While B cell responses are key, as they can mediate antibody-dependent protection, T cells can modulate B cell activity and directly contribute to the elimination of pathogen-infected cells. In the unprecedented race to develop an effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the respiratory disease coronavirus disease 2019 (COVID-19), messenger RNA (mRNA) vaccines have emerged as front runners thanks to their capacity for rapid development and ability to drive potent adaptive immune responses. In this review article, we provide an overview of the results from pre-clinical studies in animal models as well as clinical studies in humans that assessed the efficacy of SARS-CoV-2 mRNA vaccines, with a primary focus on adaptive immune responses post vaccination. View Full-Text
Keywords: SARS-CoV-2; coronavirus; mRNA vaccines; adaptive immunity; antibodies; germinal centers; long-lived plasma cells; memory B cells; T follicular helper cells; Th1 cells SARS-CoV-2; coronavirus; mRNA vaccines; adaptive immunity; antibodies; germinal centers; long-lived plasma cells; memory B cells; T follicular helper cells; Th1 cells
Show Figures

Figure 1

MDPI and ACS Style

Bettini, E.; Locci, M. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines 2021, 9, 147. https://doi.org/10.3390/vaccines9020147

AMA Style

Bettini E, Locci M. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines. 2021; 9(2):147. https://doi.org/10.3390/vaccines9020147

Chicago/Turabian Style

Bettini, Emily, and Michela Locci. 2021. "SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond" Vaccines 9, no. 2: 147. https://doi.org/10.3390/vaccines9020147

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop